These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous Vaccination. Wang J; Li P; Wu MX J Invest Dermatol; 2016 Nov; 136(11):2183-2191. PubMed ID: 27287182 [TBL] [Abstract][Full Text] [Related]
7. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998 [TBL] [Abstract][Full Text] [Related]
8. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Glenn GM; Kenney RT; Ellingsworth LR; Frech SA; Hammond SA; Zoeteweij JP Expert Rev Vaccines; 2003 Apr; 2(2):253-67. PubMed ID: 12899576 [TBL] [Abstract][Full Text] [Related]
9. Adjuvants in cutaneous vaccination: A comprehensive analysis. Oladejo M; Tijani AO; Puri A; Chablani L J Control Release; 2024 May; 369():475-492. PubMed ID: 38569943 [TBL] [Abstract][Full Text] [Related]
10. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases. Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651 [TBL] [Abstract][Full Text] [Related]
11. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein. Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819 [TBL] [Abstract][Full Text] [Related]
12. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Hammond SA; Guebre-Xabier M; Yu J; Glenn GM Crit Rev Ther Drug Carrier Syst; 2001; 18(5):503-26. PubMed ID: 11763499 [TBL] [Abstract][Full Text] [Related]
13. Modes of Action for Mucosal Vaccine Adjuvants. Aoshi T Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755 [TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvants: smart components to boost the immune system. Bastola R; Noh G; Keum T; Bashyal S; Seo JE; Choi J; Oh Y; Cho Y; Lee S Arch Pharm Res; 2017 Nov; 40(11):1238-1248. PubMed ID: 29027637 [TBL] [Abstract][Full Text] [Related]
16. Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses. Chin J; San Gil F Immunol Cell Biol; 1998 Jun; 76(3):245-55. PubMed ID: 9682968 [TBL] [Abstract][Full Text] [Related]
17. Are we entering a new age for human vaccine adjuvants? O'Hagan DT; Fox CB Expert Rev Vaccines; 2015 Jul; 14(7):909-11. PubMed ID: 25947042 [TBL] [Abstract][Full Text] [Related]
18. Mass vaccination: solutions in the skin. Glenn GM; Kenney RT Curr Top Microbiol Immunol; 2006; 304():247-68. PubMed ID: 16989274 [TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Johnston D; Bystryn JC Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898 [TBL] [Abstract][Full Text] [Related]
20. The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination. Himes R; Lee S; McMenigall K; Russell-Jones G Vaccine; 2011 Jul; 29(33):5393-8. PubMed ID: 21664219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]